688117 Cheng Du Sheng Nuo Biotec
- 23.33
- +1.37+6.24%
Cheng Du Sheng Nuo Biotec News
Shengnuo Biotechnology (688117.SH): The application for the listing approval of Citric Acid Bivalirudin active pharmaceutical ingredient has been obtained.
On July 4th, Gelon Hui announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., recently received the "Approval Letter for Listing Application of Chemical Raw Materials for Citric Acid Bivalirudin Active Pharmaceutical Ingredient" issued by the National Medical Products Administration. Citric acid bivalirudin is used for perioperative antithrombotic therapy for PCI, can specifically bind to GP IIb/IIIa receptors, and inhibit platelet aggregation by blocking the combination of fibrinogen, von Willebrand factor and other adhesion ligands with GP IIb/IIIa. Citric acid bivalirudin not only
Weight loss drug concept stocks in A-shares rose across the board, and Notai Biology hit the daily limit.
On June 20th, Bioshine Technology hit the limit up, with Shengnuo Biotechnology, Jinkai Life Sciences, Boji Medical Technology, and Hybio Pharmaceutical all following the trend.
Shengnuo Biotech (688117.SH) plans to distribute 0.2 yuan per share in 2023, with ex-rights and ex-dividends on June 14th.
Shengnuo Biotech (688117.SH) announced that its 2023 annual equity distribution plan is to distribute to all shareholders...
Shengnuo Biotech (688117.SH): The ban on 457.78,600 restricted shares was lifted on June 3
Gelonghui, May 24 | Shengnuo Biotech (688117.SH) announced that the total number of shares in circulation during the current stock listing was 457.78,600 shares. The current stock listing circulation date is June 3, 2024.
Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection
Chengdu Sirnao Biopharmaceutical, a unit of Chengdu Sheng Nuo Biotec (SHA:688117), received a drug registration certificate from China's National Medical Products Administration to produce its drug po
Express News | Shengnuo Biotech: Posaconazole injection obtained drug registration certificate
Shengnuo Biotech (688117): Deeply involved in the field of peptides, the expansion of multiple business segments is imminent
A leading company in peptide R&D and production, focusing on the peptide industry for more than 20 years. The company focuses on the field of peptide medicine and is one of the most powerful peptide R&D and production enterprises in China. The main products and services include self-developed peptide APIs and formulation products, and peptide innovation
We Think You Should Be Aware Of Some Concerning Factors In ChengDu ShengNuo BiotecLtd's (SHSE:688117) Earnings
The market for ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) stock was strong after it released a healthy earnings report last week. While the profit numbers were good, our analysis has found some
Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide mark
Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide market, and peptide APIs & CDMO are rising; 2) leading domestic peptide API companies, and production capacity construction continues to advance; 3) mastering core technology, the number of CDMO projects ranks among the highest in the country; 4) pharmaceutical business collection in exchange for price and volume, contributing to performance growth. (Mainichi Keizai Shimbun)
Shengnuo Biotech (688117) Company Information Update Report: Profit Side Flexibility Is Gradually Unleashed, New Production Capacity Is About to Be Implemented to Break Through Supply Bottlenecks
Profit side flexibility was gradually released. In 2023, the three core sub-businesses developed steadily. In 2023, the company achieved operating income of 435 million yuan, an increase of 9.93% over the previous year; net profit to mother was 70.34 million yuan, an increase of 9.08% over the previous year; deducted
Open Source Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating. The main reasons for the rating include: 1) the gradual release of profit-side flexibility, and the overall steady developme
Open Source Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating. The main reasons for the rating include: 1) the gradual release of profit-side flexibility, and the overall steady development of the three core sub-businesses; 2) “barefoot” varieties in the formulation business won the bid, and downstream demand in the API business is strong and is expected to grow rapidly; 3) Continued promotion of peptide production capacity construction, and new production capacity is about to break through supply-side bottlenecks. (Mainichi Keizai Shimbun)
Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual rep
Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual report and the 2024 quarterly report; 2) the 2023 performance grew steadily, and the volume of the pharmaceutical+pharmaceutical research business increased significantly; 3) the continuous expansion of API production capacity is expected to drive the company's performance acceleration. (Mainichi Keizai Shimbun)
Shengnuo Biotech (688117): Steady performance growth is expected to be implemented in new production capacity to drive faster performance
Investment highlights: Event: The company released the 2023 annual report and the 2024 quarterly report, achieved revenue of 404 million yuan in 2023, an increase of 9.9% over the previous year, and achieved net profit of 70 million yuan, an increase of 9.1% over the previous year, and achieved
Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the lay
Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the layout results in the three major fields of peptides are gradually being enriched; 2) production capacity expansion is accelerating, and R&D investment is increasing. (Mainichi Keizai Shimbun)
Shengnuo Biotech (688117): Comprehensive peptide layout consolidates first-mover advantage and accelerates production expansion
Performance Overview On April 22, 2024, the company announced that revenue for the full year of 2023 was 435 million yuan, up 9.93% year on year, and returned to mother/deducted non-net profit of 0.7/60 million yuan, up 9.08% year on year/
Shengnuo Biotech (688117.SH) announced its 2023 annual results, and net profit of 703.371 million yuan increased 9.08% year over year
Shengnuo Biotech (688117.SH) released its 2023 annual results report. During the reporting period, the company achieved operating income of 435 million yuan, an increase of 9.93%; net profit attributable to shareholders of listed companies was 703.371 million yuan, an increase of 9.08% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 60.208 million yuan, an increase of 6.38% year on year; basic income per share was 0.63 yuan. The company plans to distribute a cash dividend of 2.00 yuan (tax included) to all shareholders for every 10 shares.
Shengnuo Biotech (688117): The trend of leading companies in peptide APIs is accelerating their performance is clear
Incident Overview In 2024Q1, the company's revenue/net profit attributable to mothers/net profit deducted from non-mother profit/net operating cash flow were 11.00/0.96/0.93/-291 million yuan, respectively, up 12.48% /6.59 million yuan over the previous year
The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.
The concept of diet pills fluctuated and declined, with Aimeike falling more than 7%, Huadong Pharmaceutical and Zhengguang shares falling by more than 4%, and Haoyuan Pharmaceuticals, Medici, and Shengnuo Biotech.
Shengnuo Biotech (688117) Company's First Coverage Report: Focusing on the implementation of new production capacity in the entire peptide industry chain to open up room for growth
Focus on the entire peptide industry chain, and the multi-business collaborative development of Shengnuo Biotech focuses on the field of peptide pharmaceuticals, focusing on peptide raw materials, peptide preparations, and peptide CDMO businesses. The three core sectors have developed steadily in recent years, and a variety of peptide API products have been sold
Shengnuo Biotech (688117.SH): Cetrorelix acetate API received approval notice for marketing application
Glonghui, March 21丨Shengnuo Biopharmaceutical Co., Ltd. (688117.SH) announced that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Chemical Ingredient Marketing Application Approval Notice” issued by the State Drug Administration. Cetrorelix acetate is a synthetic decapeptide. The formulation is an injectable gonadotropin-releasing hormone (GnRH) antagonist, which is used to assist reproduction and inhibit the surge of early progesterone. Studies have shown that cetrorelix acetate has good curative effects on diseases such as ovarian cancer, prostate cancer, uterine fibroma, and endometriosis, and is also good for pre-benign diseases
Analysis
Price Target
No Data
